Literature DB >> 23512228

Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjects.

John R Senior.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23512228     DOI： 10.1002/pds.3435

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  2 in total

1.  Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.

Authors:  Emiliano Calvo; Analia Azaro; Jordi Rodon; Luc Dirix; Manon Huizing; Francis Mark Senecal; Patricia LoRusso; Lorrin Yee; Italo Poggesi; Jan de Jong; Spyros Triantos; Youn C Park; Roland E Knoblauch; Trilok V Parekh; George D Demetri; Margaret von Mehren
Journal:  Invest New Drugs       Date:  2017-11-27       Impact factor: 3.850

Review 2.  Liver safety assessment in special populations (hepatitis B, C, and oncology trials).

Authors:  Gerd A Kullak-Ublick; Michael Merz; Louis Griffel; Neil Kaplowitz; Paul B Watkins
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.